Literature DB >> 29220302

Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.

Brigitte C Widemann1, Antoine Italiano1.   

Abstract

Undifferentiated pleomorphic sarcomas, myxofibrosarcomas, and malignant peripheral nerve sheath tumors are characterized by complex genomic characteristics and aggressive clinical behavior. Recent advances in the understanding of the pathogenesis of these tumors may allow for the development of more-effective innovative therapeutic strategies, including immunotherapies. This review describes the current knowledge of the epidemiology, clinical presentation, treatment, and pathogenesis of these tumors and highlights ongoing and future research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29220302      PMCID: PMC5759316          DOI: 10.1200/JCO.2017.75.3467

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  64 in total

1.  Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease.

Authors:  Brendan Waters; David M Panicek; Robert A Lefkowitz; Cristina R Antonescu; John H Healey; Edward A Athanasian; Murray F Brennan
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

2.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

Authors:  Elina Uusitalo; Matti Rantanen; Roope A Kallionpää; Minna Pöyhönen; Jussi Leppävirta; Heli Ylä-Outinen; Vincent M Riccardi; Eero Pukkala; Janne Pitkäniemi; Sirkku Peltonen; Juha Peltonen
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Authors:  Alessandro Gronchi; Stefano Ferrari; Vittorio Quagliuolo; Javier Martin Broto; Antonio Lopez Pousa; Giovanni Grignani; Umberto Basso; Jean-Yves Blay; Oscar Tendero; Robert Diaz Beveridge; Virginia Ferraresi; Iwona Lugowska; Domenico Franco Merlo; Valeria Fontana; Emanuela Marchesi; Davide Maria Donati; Elena Palassini; Emanuela Palmerini; Rita De Sanctis; Carlo Morosi; Silvia Stacchiotti; Silvia Bagué; Jean Michelle Coindre; Angelo Paolo Dei Tos; Piero Picci; Paolo Bruzzi; Paolo Giovanni Casali
Journal:  Lancet Oncol       Date:  2017-05-09       Impact factor: 41.316

4.  Karyotypic "state" as a potential determinant for anticancer drug discovery.

Authors:  Anna V Roschke; Samir Lababidi; Giovanni Tonon; Kristen S Gehlhaus; Kimberly Bussey; John N Weinstein; Ilan R Kirsch
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-09       Impact factor: 11.205

Review 5.  Malignant fibrous histiocytoma: changing perceptions and management challenges.

Authors:  Michael T Henderson; S Tyler Hollmig
Journal:  J Am Acad Dermatol       Date:  2012-06-05       Impact factor: 11.527

6.  Recurrent TRIO Fusion in Nontranslocation-Related Sarcomas.

Authors:  Lucile Delespaul; Tom Lesluyes; Gaëlle Pérot; Céline Brulard; Lydia Lartigue; Jessica Baud; Pauline Lagarde; Sophie Le Guellec; Agnès Neuville; Philippe Terrier; Dominique Vince-Ranchère; Susanne Schmidt; Anne Debant; Jean-Michel Coindre; Frédéric Chibon
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

7.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 8.  Malignant peripheral nerve sheath tumors.

Authors:  Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki
Journal:  Oncologist       Date:  2014-01-27

9.  Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling.

Authors:  Y-F Lee; M John; S Edwards; J Clark; P Flohr; K Maillard; M Edema; L Baker; D C Mangham; R Grimer; R Wooster; J M Thomas; C Fisher; I Judson; C S Cooper
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

Review 10.  Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Authors:  Karlyne M Reilly; AeRang Kim; Jaishri Blakely; Rosalie E Ferner; David H Gutmann; Eric Legius; Markku M Miettinen; R Lor Randall; Nancy Ratner; N L Jumbé; Annette Bakker; David Viskochil; Brigitte C Widemann; Douglas R Stewart
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

View more
  23 in total

1.  Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.

Authors:  Angela D Bhalla; Sharon M Landers; Anand K Singh; Jace P Landry; Michelle G Yeagley; Gabryella S B Myerson; Cristian B Delgado-Baez; Stephanie Dunnand; Theresa Nguyen; Xiaoyan Ma; Svetlana Bolshakov; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Xizeng Mao; Xingzhi Song; Alexander J Lazar; Ian E McCutcheon; John M Slopis; Joseph A Ludwig; Dina C Lev; Kunal Rai; Keila E Torres
Journal:  Lab Invest       Date:  2022-02-28       Impact factor: 5.662

2.  Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.

Authors:  Ashley M Fuller; Ann DeVine; Ileana Murazzi; Nicola J Mason; Kristy Weber; T S Karin Eisinger-Mathason
Journal:  Cell Oncol (Dordr)       Date:  2022-10-01       Impact factor: 7.051

3.  An extremely scarce incidence of primary Undifferentiated Pleomorphic Sarcoma of the Scalp of a 52-year-old female - A Case Report.

Authors:  Omar Al Laham; Gheed Abdul Khalek; Hazar Alboushi; Abd Al Hameed Al Mohammad; Mohamad Almaydaani; Alaa Alhanwt
Journal:  Int J Surg Case Rep       Date:  2022-09-19

Review 4.  WHO Pathology: Highlights of the 2020 Sarcoma Update.

Authors:  Inga-Marie Schaefer; Alessandro Gronchi
Journal:  Surg Oncol Clin N Am       Date:  2022-05-31       Impact factor: 2.402

5.  A matched cohort study of radio-chemotherapy versus radiotherapy alone in soft tissue sarcoma patients.

Authors:  Daniela Greto; Mauro Loi; Francesca Terziani; Luca Visani; Pietro Garlatti; Monica Lo Russo; Ausilia Teriaca; Cristina Muntoni; Camilla Delli Paoli; Juliana Topulli; Domenico Campanacci; Giovanni Beltrami; Guido Scoccianti; Pierluigi Bonomo; Isacco Desideri; Giulio Francolini; Lorenzo Livi
Journal:  Radiol Med       Date:  2018-09-12       Impact factor: 3.469

6.  RSF1 requires CEBP/β and hSNF2H to promote IL-1β-mediated angiogenesis: the clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas.

Authors:  Chien-Feng Li; Ti-Chen Chan; Cheng-I Wang; Fu-Min Fang; Po-Chun Lin; Shih-Chen Yu; Hsuan-Ying Huang
Journal:  Angiogenesis       Date:  2021-01-26       Impact factor: 10.658

7.  Primary undifferentiated pleomorphic sarcoma in oral-maxillary area: retrospective study and molecular analysis.

Authors:  Yuanhe You; Rongxin Shi; Meilu Dai; Zhong Du; Zhuowei Tian; Guisong Xu; Lizhen Wang; Yan'an Wang; Meng Xiao
Journal:  Histol Histopathol       Date:  2021-07-20       Impact factor: 2.303

8.  Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.

Authors:  Laurene S Cheung; Lingling Chen; Teniola F Oke; Thomas B Schaffer; Karim Boudadi; Jillian T Ngo; John McMahon Gross; Holly Kemberling; Luis A Diaz; Evan Lipson; John-WIlliam Sidhom; Janis Taube; Robert Anders; Drew M Pardoll; Dung T Le; Christian F Meyer; Nicolas Llosa
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

9.  Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Tomohiko Ito; Masao Akagi
Journal:  Eur J Histochem       Date:  2021-07-02       Impact factor: 3.188

Review 10.  The epigenomics of sarcoma.

Authors:  Benjamin A Nacev; Kevin B Jones; Andrew M Intlekofer; Jamie S E Yu; C David Allis; William D Tap; Marc Ladanyi; Torsten O Nielsen
Journal:  Nat Rev Cancer       Date:  2020-08-11       Impact factor: 69.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.